AnYi

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of AnYi

Quick Facts

Property Description
Active ingredient Acetaminophen (Paracetamol)
Forms Tablet, Caplet, Oral Solution, Suppository, Intravenous Infusion
Pharmacological class Non-Opioid Analgesic, Antipyretic, Para-Aminophenol Derivative
Common purpose Pain Relief and Fever Reduction
Origin Synthetic

What Type of Medicine is AnYi? (Identity and Classification)

AnYi is a preparation containing the active ingredient Acetaminophen, an established chemical compound known internationally as Paracetamol. This Synthetic agent is classified as a Non-Opioid Analgesic and Antipyretic, meaning its primary therapeutic role is to provide relief from pain and reduce fever. Acetaminophen is chemically defined as a Para-Aminophenol Derivative. This distinction is clinically recognized as differentiating its mechanism of action, which primarily occurs within the central nervous system, from that of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Ibuprofen, which typically exhibit more pronounced peripheral anti-inflammatory effects. Acetaminophen is an effective agent used to treat minor aches and pains and to bring down a high temperature, serving as a widely used, foundational option for these symptoms.

Composition, Forms, and General Purpose

The general purpose of the AnYi preparation is to offer systemic support in managing discomfort and facilitating the normalization of an elevated core body temperature. The compound is a recognized first-line agent for general pain conditions. The medicine is delivered in numerous Dosage forms, including Tablet, Capsule, Oral Solution, and Suppository, as well as a sterile solution for Intravenous (IV) Infusion. These varied forms enable administration via Oral, Rectal, and Parenteral routes, ensuring utility across different patient populations, including Pediatrics, where a liquid or suppository may be necessary. While typically provided as a single-ingredient product, its inherent compatibility means Acetaminophen is a common and versatile component in many other fixed-dose combination products.

Regulatory References

  1. Para-Aminophenol Derivative
  2. Acetaminophen is an effective agent used to treat minor aches and pains and to bring down a high temperature

What side effects are possible with AnYi?

Possible Side Effects and Safety Information for AnYi

The safety profile of a medicine is defined by regulatory documents through a structured classification of adverse reactions and special warnings.

Serious and Clinically Significant Risks

Regulatory labeling highlights Serious Adverse Reactions (SARs)—events that may be life-threatening, result in significant disability, require hospitalization, or lead to death. The most critical risks may be communicated via a Boxed Warning if the potential harm is severe and may be mitigated by appropriate monitoring or restriction of use. Clinically significant risks are identified in the Warnings and Precautions section, detailing risks that require specific monitoring, such as effects on the cardiovascular, hepatic, or renal systems.

Common Adverse Reactions

Adverse reactions observed in clinical trials are categorized by the System Organ Class (SOC) affected (e.g., Gastrointestinal Disorders, Nervous System Disorders) and classified by frequency using established regulatory bands:

  • Very Common: Occurs in 1 in 10 patients or more.
  • Common: Occurs in less than 1 in 10 but at least 1 in 100 patients.
  • Uncommon / Rare: Events with lower observed frequency (e.g., less than 1 in 1,000 or 1 in 10,000 patients) are also documented to provide a comprehensive risk profile.

Safety Restrictions and Monitoring

Contraindications are absolute restrictions, stating that the drug must not be used in patients with specific pre-existing conditions (e.g., severe organ failure, known hypersensitivity). Population-specific safety notes address modified risks for patient groups such as the elderly, children, or those with impaired liver or kidney function, where dose adjustment or increased monitoring may be required. Regulatory documents may also cite dose-related patterns where the frequency or severity of certain reactions increases with a higher dose or prolonged exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of AnYi (Acetaminophen/Paracetamol) presents an officially documented risk of severe, potentially fatal hepatotoxicity (liver damage). Patients are officially required to seek immediate medical attention for any suspected overdose, even if initial clinical signs are absent or mild, as the most critical damage is often delayed and progressive.

Documented Overdose Manifestations

Initial presentations documented in regulatory materials often include non-specific symptoms such as Nausea, Vomiting, Diaphoresis (sweating), and general Malaise. The principal danger is the progression to severe outcomes including Hepatic Failure, Hepatic Encephalopathy, Coma, and Death. Acute Renal Tubular Necrosis and Myocardial Damage are also documented complications.

Emergency Actions and Management

Government regulatory guidance mandates that patients contact emergency services immediately upon suspected overdose. The specific antidote, N-acetylcysteine (NAC), is required for treatment and its effectiveness is time-critical. Management protocols officially describe the need for Hospital Observation and Monitoring for a minimum of 24 hours, with continuous tracking of liver function (enzymes) and coagulation status. Certain populations, including those with Chronic Alcohol Use or Pre-existing Liver Impairment, are noted in labeling as having increased susceptibility to severe outcomes.

Therapeutic Uses of AnYi

AnYi is widely applied to address symptoms related to physical discomfort and systemic imbalance. This medication is commonly used to help with symptomatic relief across a spectrum of mild-to-moderate pain and for reducing elevated core body temperature.

Therapeutic Domains and Symptom Management

This therapeutic domain covers conditions presenting with acute episodes, such as tension headache, musculoskeletal aches, dental pain, and the fever and discomfort associated with the common cold and influenza. It is also relevant in situations involving recurrent manifestations, including painful menstruation and the symptomatic distress following routine immunizations or minor procedures. The symptomatic assistance may help patients cope more steadily with symptom fluctuations, contributing to improved day-to-day comfort when symptoms interfere with routine activities.

Quick Fact Used to ease the overall symptom burden

It is often applied during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden. It is commonly used when sudden discomfort requires needed symptomatic support.

Regulatory References

  1. Health Canada information on Acetaminophen

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use AnYi

Official regulatory documents define strict population eligibility criteria for AnYi (Acetaminophen/Paracetamol), encompassing absolute prohibitions and conditions that require restricted use.

Populations for Whom Use is Contraindicated

The medicine is contraindicated and must not be used by two primary patient groups:

  • Individuals with a known hypersensitivity or allergy to acetaminophen or any ingredient within the specific formulation.
  • Patients with severe active hepatic impairment or acute liver failure, as this organ is essential for the body to process the medicine.

Age and Condition-Specific Eligibility Rules

Category Regulatory Status
Age Eligibility Approved for use across Adults and Adolescents. Certain specific formulations (e.g., intravenous) may have official statements noting that efficacy has not been established in pediatric patients younger than two years of age.
Restricted Use Conditions Caution is advised for patients with severe renal impairment, chronic malnutrition, or a history of chronic alcohol abuse. Eligibility is conditional on careful assessment due to the heightened risk profile in these groups.
Pregnancy and Lactation Use during pregnancy and lactation is permitted but officially recommended only at the lowest effective dose for the shortest duration necessary.

These constraints establish clear boundaries, defining which populations are absolutely excluded and which require conditional use as mandated by regulatory authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

AnYi (Acetaminophen/Paracetamol) is subject to several officially documented interaction patterns primarily focusing on its metabolism and clearance, as detailed in regulatory labeling.

Co-administration with other products containing Acetaminophen is strictly restricted by regulatory authorities to prevent the cumulative risk of exceeding the maximum recommended dose. This restriction is crucial due to the potential for acute liver failure.

Interactions that modify systemic exposure include those with Probenecid, which reduces AnYi's clearance and increases plasma levels. Conversely, Colestyramine reduces absorption and requires mandatory separation of administration: AnYi must be taken at least one hour before or several hours after Colestyramine. The absorption rate is increased when taken with Metoclopramide or Domperidone.

A key pharmacodynamic interaction involves Warfarin and related Coumarin anticoagulants. Regulatory labeling states that prolonged, regular daily use of AnYi may enhance the anticoagulant effect, officially increasing the risk of bleeding.

The risk of hepatotoxicity is officially documented as increased when AnYi is co-administered with Enzyme Inducers such as Phenytoin or Carbamazepine, or in individuals with chronic heavy alcohol use. This specific hazard is also noted as being heightened in populations with pre-existing hepatic impairment.

Mechanism of Action

Central Resetting of the Body's Thermoregulatory Set-Point

The drug acts primarily by inhibiting Cyclooxygenase ( COX) enzymes within the Central Nervous System, specifically in the hypothalamus. This targeted enzyme inhibition reduces the synthesis of the signaling molecule Prostaglandin E2 ( PGE2), which is responsible for elevating the body's thermal set-point. This mechanism initiates a physiological cascade of enhanced heat dissipation (vasodilation and sweating), which results in the resetting of the hypothalamic thermoregulatory set-point and activation of heat-loss mechanisms.


Dual Central Pathway for Nociceptive Modulation

The mechanism for modulating nociceptive signaling is two-fold and occurs centrally. It involves the direct effect of COX inhibition in the spinal cord and brain to modulate nociceptive signaling. Additionally, the drug's metabolite, AM404, engages the endocannabinoid system by enhancing signaling at CB1 and TRPV1 receptors. This action potentiates the descending serotonergic pathways that mediate the inhibition of nociceptive signal transmission, contributing to central modulation of nociceptive input.


Physiological Constraint: Peroxide Sensitivity

The drug's mechanism of enzyme inhibition is constrained by its sensitivity to peroxides (reactive oxygen species), which are released in high concentrations at sites of peripheral inflammation. The presence of peroxides essentially prevents the drug from effectively inhibiting COX activity in the periphery. This functional limitation ensures that the drug primarily influences central processes and limits the generation of peripheral anti-inflammatory physiological consequences.

Dosage and Administration Information

Administration and Dosage Principles

AnYi is administered following standardized parameters across its diverse dosage forms. The established routes of administration include oral (via tablets, capsules, or solutions), rectal (via suppositories), and intravenous (IV) infusion for use strictly in clinical settings. The medicine’s usage pattern is primarily intermittent and as-needed (PRN), guided by strict dosage limits.


Official Dosing Regimens

The standard labeled regimen for adults specifies a typical single oral dose range of 325 mg to 1000 mg. Crucially, the maximum total daily dose from all sources of the active ingredient must not exceed 4000 mg (4 g), a limit established to govern cumulative systemic intake. The required minimum interval between immediate-release doses is 4 to 6 hours to maintain the necessary time separation for subsequent administration.


Contextual Use and Adjustments

Administration context is form-dependent. For instance, the sterile IV solution must be delivered as a controlled 15-minute infusion. Certain oral forms, such as effervescent tablets, require complete dissolution in water before intake. Dosing protocols incorporate population-specific rules, mandating weight-based calculations for pediatric patients and requiring a reduced maximum daily dose for individuals with known hepatic impairment. The structural administration principle dictates that patients must always account for total daily intake across all combination products to stay within the recommended limits.

Recent Clinical Evidence

Research Evidence / Overview of Studies for AnYi


Evidence for Use in Managing Acute Mild-to-Moderate Pain

The research exploring AnYi in conditions characterized by episodic, mild-to-moderate physical discomfort is drawn primarily from numerous short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies included the general adult population, adolescents, and specific acute groups like patients recovering from dental procedures. Research examined outcomes related to physical discomfort by measuring changes in patient-reported outcomes describing perceived discomfort.

Findings describe patterns observed in the studies where measurements of reported physical discomfort were documented shortly after administration. Research also monitored the use of rescue medication by patients during the study interval. The existing body of research provides limited information for long-term outcomes, meaning research exploring the agent’s use as a monotherapy for conditions characterized by chronic, long-term pain management is not well established.


Evidence for Use in Fever Reduction (Antipyresis)

The research exploring AnYi for fever (pyrexia) draws from extensive RCTs, Systematic Reviews, and large Observational Studies. The research examined outcomes related to physiological strain by monitoring measurements of Core Body Temperature. The populations studied included Pediatrics (infants, children, and adolescents) and adults experiencing fever associated with common self-limiting illnesses.

Studies monitored Core Body Temperature measurements following administration. The data show patterns related to perceived discomfort over defined, short time intervals. While studies contribute to the broader evidence landscape for fever management, the evidence is limited in defining whether the change in temperature was associated with an impact on the progression or severity of the underlying condition causing the fever.


What Is Still Uncertain and Research Gaps

Despite the comprehensive nature of the short-term evidence, several research limitations and gaps exist. The evidence quality varies across studies when moving beyond the most basic, acute indications. For complex or chronic conditions, findings were mixed or the certainty remains low. Comparative evidence is lacking for certain conditions, and the results apply only to the specific conditions and populations studied. Research is ongoing to better understand symptom patterns across a wider range of clinical scenarios.

Key Studies & References Health Canada: Acetaminophen - What you need to know

Frequently Asked Questions (FAQ)

Common questions about AnYi (FAQ)

Q: Is AnYi a long-term treatment or just for short periods?

A: Official regulatory guidance concerning over-the-counter use limits AnYi for symptom management over short durations. Specifically, use for pain is generally limited to no more than 10 days, and use for fever is limited to no more than 3 days. Use extending beyond these durations is typically subject to clinical guidance.

Q: What are the most common side effects people talk about with AnYi?

A: Official product information focuses on communicating the most significant potential hazards. The product label highlights serious warnings regarding the risk of severe liver damage and the potential for severe skin reactions, such as blistering or rash. While other less severe side effects may occur, these serious risks are noted for user awareness and monitoring.

Q: Can older adults use AnYi without special concern?

A: Official documents include population-specific safety notes regarding the use of AnYi in older adults. These notes indicate that modified use, such as a dose adjustment or increased clinical monitoring, may be required. This is a general precaution cited in regulatory documents.

Q: Is AnYi addictive or does it cause withdrawal symptoms?

A: AnYi is officially classified as a non-opioid analgesic. This means that the medicine is not associated with the same risks of physical dependence or addiction that are seen with opioid pain relievers.

Q: Does AnYi interact with common over-the-counter pain relievers?

A: Regulatory labeling strictly advises against taking AnYi with any other medication that contains acetaminophen. This warning is in place to prevent accidental overdose. Consultation with a healthcare professional is advisable before combining AnYi with other pain relievers that do not contain acetaminophen.

Q: Do I need any special tests or monitoring while taking AnYi?

A: Official safety documentation recommends clinical monitoring of hepatic (liver) function in certain populations. This monitoring is advised especially for individuals who have underlying liver disease or those who may be taking high doses of the medication for an extended period.

Q: Can AnYi interact with non-prescription cold or flu medicines?

A: Yes. The official safety warning explicitly states not to use AnYi with any other drug containing acetaminophen, whether prescription or non-prescription. This is a critical point to remember, as many common non-prescription cold and flu multi-symptom medicines include this ingredient.

Q: Why are there different strengths or formulations of AnYi available?

A: Different strengths and formulations, such as liquid solutions or varying tablet sizes, are available for utility in precise dosing. This variety allows for accurate, appropriate administration based on the patient's age or weight—particularly in children—and helps ensure that the established maximum daily dose is not exceeded.

Q: How quickly should I expect AnYi to start working?

A: According to general consumer information on the active ingredient, AnYi is typically used for the temporary relief of symptoms like pain and fever. The effects of the medicine generally begin soon after it is administered.

Q: Why do some people say AnYi makes them feel tired?

A: Official consumer warnings list extreme tiredness or lack of energy as a symptom that may be associated with an overdose of the medication. If such a symptom occurs, consulting a healthcare professional is advisable, as this may be a sign of a severe reaction.

Q: What happens if I forget to take my AnYi dose?

A: Since AnYi is typically used as needed, official guidance indicates that if a dose is missed, taking it as soon as it is remembered may be appropriate. If it is almost time for the next scheduled dose, skipping the missed one and resuming the regular pattern is typically recommended. The minimum time interval specified between doses should be observed.

Q: Does AnYi affect my ability to drive or operate machinery?

A: The product label should be reviewed for specific warnings. Official safety guidance indicates that if rare side effects, such as dizziness, blurred vision, or drowsiness, occur, avoiding driving or operating heavy machinery is generally recommended until one is certain how the medicine affects them.

Q: Can AnYi affect my blood pressure?

A: Official cautionary statements advise individuals with pre-existing conditions like high blood pressure or heart disease to consult a healthcare professional before using AnYi. This is a general precaution cited in regulatory documents.

Q: Does AnYi interact with birth control pills?

A: Studies cited in professional regulatory references indicate that oral contraceptives may cause a slight decrease or delay in the effects of AnYi. However, official sources generally consider concurrent administration at usual therapeutic dosages to pose no significant additional risk.

Q: Can AnYi interact with medications for depression or anxiety?

A: Official interaction checkers generally find no major interaction risk between pure AnYi (Acetaminophen) and common selective serotonin reuptake inhibitors (SSRIs) or other typical medications for depression or anxiety. However, it is always important to verify all current medications with a healthcare professional.

Q: Does AnYi have a specific classification (e.g., controlled substance)?

A: AnYi, as a single-ingredient product containing only Acetaminophen/Paracetamol, is not classified as a controlled substance under the United States Drug Enforcement Administration (DEA) scheduling system.

Q: Does AnYi affect laboratory test results?

A: Yes, official safety information indicates that AnYi may affect the results of certain laboratory tests. Patients are advised to inform their doctor and laboratory personnel that they are taking the medicine before any test is conducted.

How should AnYi be stored and disposed of?

How to Store and Dispose of AnYi

The storage and disposal of AnYi (acetaminophen/paracetamol) must strictly adhere to regulatory requirements to ensure product integrity and household safety.

Storage Requirements

AnYi must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with brief excursions permitted up to 30 C (86 F). The product must be protected from light and moisture and should be kept in its original container with the cap tightly closed. Certain liquid and suppository forms carry the specific instruction to not freeze.

Child Safety and Disposal

It is officially mandated that AnYi be stored out of the reach and sight of children and pets. For disposal, unused or expired medicine should be taken to an official drug take-back program. If a program is unavailable, the medicine must be mixed with an undesirable substance and sealed before being placed in the trash, in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of AnYi found in:

A-Z Index: